Zoetis

$223.33 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Zoetis

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Stock Analysis

last close $223.19
1-mo return 5.2%
3-mo return 6.7%
avg daily vol. 1.46M
52-week high 228.89
52-week low 141.41
market cap. $103.8B
forward pe 45.4
annual div. 1
roe 47.9%
ltg forecast 13.6%
dividend yield 0.45%
annual rev. $7.6B
inst own. 92.7%
baraka

Subscribe now for daily local and international financial news

Subscribe